PDF(Pubmed)
Abstract：
RFX, a rifamycin-based antibacterial agent obtained by the culture of the actinomycete Streptomyces mediterranei, has a broad antibacterial spectrum covering gram- positive, gram-negative, aerobic, and anaerobic bacteria. RFX is an antibiotic that elicits its effect by inhibiting bacterial RNA synthesis. When administered orally, its intestinal absorption is extremely low (<0.4%), restricting antibacterial activity mainly in the intestinal tract, with few systemic side effects. RFX has been recommended by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver guidelines for the treatment of HE. RFX may contribute to restore hepatic function and to decrease the development of liver fibrosis. Its efficacy has been shown in patients with previous hepatic encephalopathy and several complications, such as infections, including spontaneous bacterial peritonitis, ascites and oesophageal variceal bleeding. Thus, RFX has an outstanding role in the therapeutic arsenal in hepatic cirrhosis, under the concept of disease modifier.
摘要：
RFX,一种基于利福霉素的抗菌剂，通过放线菌地中海链霉菌的培养获得，具有广泛的抗菌谱，涵盖革兰氏阳性，革兰氏阴性,有氧,和厌氧细菌。RFX是一种通过抑制细菌RNA合成来引发其作用的抗生素。口服时，它的肠道吸收极低（<0.4％），限制抗菌活性主要在肠道，几乎没有全身副作用。RFX已被美国肝病研究协会和欧洲肝脏研究协会推荐用于HE治疗的指南。RFX可能有助于恢复肝功能和减少肝纤维化的发展。其疗效已显示在先前的肝性脑病和几种并发症的患者，如感染，包括自发性细菌性腹膜炎,腹水和食管静脉曲张出血。因此，RFX在肝硬化的治疗武器库中具有突出的作用，在疾病修饰的概念下。
